Database | Recombinant Antibodies And Mimetics Database

What can we help you find?

You are searching for:

Category A

Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Category B

Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation

Category C

Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation

Category D

Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation

Category E

Original source/host: Animal
Discovery method: immunisation-based selection post 2020
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Category F

Original source/host: Animal
Discovery method: immunisation-based selection post 2020
Production: Recombinant expression with animal-derived biomaterials used in production or final formulation

Category G

Original source/host: Unknown
Discovery method: Unknown
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Uncategorised Antibodies

Uncategorised Antibodies have Antibody/Binder Origins set in such a way as to prevent them from being assigned to a valid Antibody Category.

Click here to view all Antibody Category descriptions and to search directly by Antibody Category

Category A
- Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
- Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search
Category B
- Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
- Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
- Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
- Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation
Search
Category C
- Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
- Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
- Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
Search
Category D
- Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
- Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
- Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
Search
Category E
- Original source/host: Animal
- Discovery method: immunisation-based selection post 2020
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search
Category F
- Original source/host: Animal
- Discovery method: immunisation-based selection post 2020
- Production: Recombinant expression with animal-derived biomaterials used in production or final formulation
Search
Category G
- Original source/host: Unknown
- Discovery method: Unknown
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search

2661-2670 of 4090 results

Catalogue Number:

PX-TA1832

Category:

Elranatamab Biosimilar – Anti-TNFRSF17/CD3E mAb – Research Grade

Target:	TNFRSF17/CD3E
Target Alias Name:	Elranatamab//TNFRSF17/CD3E/anti-TNFRSF17/CD3E
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG2 Kappa/IgG2 Kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1192

Category:

Elsilimomab Biosimilar – Anti-IL6 mAb – Research Grade

Target:	IL6
Target Alias Name:	Elsilimomab/B-E8/IL6/anti-IL6
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-nd
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA2115

Category:

Eltrekibart Biosimilar – Anti-CXCL1 mAb – Research Grade

Target:	CXCL1
Species Reactivity:	Human
Application:	ELISA
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1662

Category:

Eluvixtamab Biosimilar – Anti-CD33/CD3E mAb – Research Grade

Target:	CD33/CD3E
Target Alias Name:	Eluvixtamab/A CD33/CD3 BISPECIFIC T-CELL ENGAGER ANTIBODY FOR ACUTE MYELOID LEUKEMIA THERAPY/ AMG 330/ AMG-330/ ELUVIXTAMAB/ ELUVIXTAMAB/CD33/CD3E/anti-CD33/CD3E
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	Bispecific scFvKappa/Lambda
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1356

Category:

Emactuzumab Biosimilar – Anti-CSF1R/ CD115 mAb – Research Grade

Target:	CSF1R/ CD115
Target Alias Name:	Emactuzumab/RG7155/RO5509554/CSF1R/ CD115/anti-CSF1R/ CD115
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1450

Category:

Emapalumab Biosimilar – Anti-IFNG mAb – Research Grade

Target:	IFNG
Target Alias Name:	Emapalumab/NI-0501/emapalumab-lzsg/IFNG /anti-IFNG
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-lambda
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1663

Category:

Emerfetamab Biosimilar – Anti-CD33/CD3E mAb – Research Grade

Target:	CD33/CD3E
Target Alias Name:	Emerfetamab/EMERFETAMAB [INN]/CD33/CD3E/anti-CD33/CD3E
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	Bispecific scFv/Kappa/Lambda
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1893

Category:

Emfizatamab Biosimilar – Anti-CD3e/CD19/CD274/TNFRSF9 mAb – Research Grade

Target:	CD3e/CD19/CD274/TNFRSF9
Target Alias Name:	Emfizatamab
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	scFv-G1-scFv-scFv/ L-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1351

Category:

Emibetuzumab Biosimilar – Anti-MET/ RCCP2 mAb – Research Grade

Target:	MET/ RCCP2
Target Alias Name:	Emibetuzumab/LA480/LY-2875358/MET/ RCCP2/anti-MET/ RCCP2
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1394

Category:

Emicizumab Biosimilar – Anti-F10/ F9 activated form mAb – Research Grade

Target:	F10/ F9 activated form
Target Alias Name:	Emicizumab/ACE-910/RG6013/hBS910/F10/ F9 activated form/anti-F10/ F9 activated form
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Viewing 2661-2670 of 4090 results

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.